Only two in ten eligible patients receive CAR-T: closing the gap starts in manufacturing

Abstract

Only around 20% of eligible US patients currently receive CAR-T therapy. Drawing on the Cell & Gene Therapy Insights CAR-T Special Interest Group, this infographic examines the manufacturing barriers behind that gap and compares three routes to wider access: autologous, allogeneic, and in vivo CAR-T.